NASDAQ$ESTA
Establishment Labs Holdings Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Establishment Labs reported record fourth quarter financial results and submitted Module Four to U.S. FDA for Premarket Approval of Motiva.
Establishment Labs reported a record fourth quarter with worldwide sales of $43.8 million, a 24.1% increase year-over-year. The company submitted the fourth and final module to the U.S. FDA for premarket approval of Motiva Implants and provided 2023 revenue guidance of $200 million to $210 million.
- Submitted fourth and final module to U.S. FDA for premarket approval of Motiva Implants®.
- 2023 guidance of $200 million to $210 million, an increase of 24% to 30% over 2022.
- Fourth quarter worldwide sales of $43.8 million, a 24.1% year-over-year increase and a new quarterly record.
- Cash balance of $66.4 million as of December 31, 2022.
Headline financials
Revenue & EPS history
Establishment Labs · Revenue · Quarterly
$43.8M
Forward guidance
Establishment Labs projects a groundbreaking year in 2023, aiming for $500 million by 2026, with revenue guidance of $200 million to $210 million.
Tailwinds
- Commercial sales of Mia Femtech are progressing.
- Approval in China is expected in the first half of 2023, gaining entry into the second largest global market.
- Module four of modular PMA submitted to the U.S. FDA, bringing closer to approval of Motiva in the United States.
- New Sulàyöm campus will undergo validation and begin manufacturing this year, bringing significant new capabilities in R&D, medical education, and media.
- Defining what a women’s health company can do to raise the standards in breast aesthetics and reconstruction.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+1.5%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.4%
Avg return
30 days after
56%
18 / 32 earnings
Positive
+22.5%
Q3 2025
Best reaction
-26.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -4.3% | +2.9% | |
| Q4 2025 | -1.9% | +5.0% | -20.1% | |
| Q3 2025 | +22.5% | +37.0% | +43.2% | |
| Q1 2025 | +4.9% | +5.1% | +14.2% | |
| Q4 2024 | +17.9% | +28.1% | +12.1% | |
| Q3 2024 | -5.2% | -13.2% | -10.0% | |
| Q2 2024 | +3.4% | +20.6% | +23.5% | |
| Q1 2024 | +5.4% | +4.2% | -10.8% | |
| Q4 2023 | +15.1% | +19.6% | +28.2% | |
| Q3 2023 | -26.0% | -36.1% | -31.7% | |
| Q2 2023 | -8.4% | -12.0% | -12.2% | |
| Q1 2023 | +1.8% | -1.6% | -1.9% | |
| Q4 2022 | +7.2% | +10.3% | +0.3% | |
| Q3 2022 | -7.7% | +11.1% | +27.1% | |
| Q2 2022 | -3.0% | +1.3% | -0.4% | |
| Q1 2022 | -10.5% | -10.1% | +2.3% | |
| Q4 2021 | +3.3% | +1.6% | +11.5% | |
| Q3 2021 | -10.6% | -14.3% | -15.2% | |
| Q2 2021 | +6.0% | -3.7% | -3.1% | |
| Q1 2021 | -0.6% | -1.8% | +8.9% | |
| Q4 2020 | +0.4% | -6.8% | +9.5% | |
| Q3 2020 | +8.9% | -0.4% | +22.6% | |
| Q2 2020 | +6.2% | +7.3% | +9.3% | |
| Q1 2020 | +2.9% | +0.5% | +15.3% | |
| Q4 2019 | +4.5% | -16.4% | +0.4% | |
| Q3 2019 | -0.3% | +0.5% | +7.8% | |
| Q2 2019 | -5.2% | -10.6% | -10.2% | |
| Q1 2019 | +1.5% | -0.3% | -15.9% | |
| Q4 2018 | -1.9% | -4.9% | -15.2% | |
| Q3 2017 | +10.3% | +4.5% | -6.2% | |
| Q3 2018 | +10.3% | +4.5% | -6.2% | |
| Q2 2018 | -2.7% | -2.9% | -3.4% | |
| Q4 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro